Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -

Europäische Union - Deutsch - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel-hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotische mittel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - ezetimib -

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lohmann pharma herstellung gmbh (4402327) - (2-diethylaminoethyl)[(3s,6r,7r)-2,2-dimethyl-6-(2-phenylacetamido)penam-3-carboxylat]-hydroiodid - pulver und lösungsmittel zur herstellung einer injektionssuspension - (2-diethylaminoethyl)[(3s,6r,7r)-2,2-dimethyl-6-(2-phenylacetamido)penam-3-carboxylat]-hydroiodid (05532) 1 gramm; (2-diethylaminoethyl)[(3s,6r,7r)-2,2-dimethyl-6-(2-phenylacetamido)penam-3-carboxylat]-hydroiodid (05532) 277,8 milligramm - rind

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - galantaminhydrobromid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; galantaminhydrobromid (07381) 30,75 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - galantaminhydrobromid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; galantaminhydrobromid (07381) 20,5 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - galantaminhydrobromid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; galantaminhydrobromid (07381) 10,25 milligramm

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

apomedica pharmazeutische produkte gmbh - vitis viniferae folium (auszug) -